Ella Morey
Impact in
- Infectious Diseases top 0.2%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Modeling and Simulation top 1%
- COVID-19 epidemiological studies
Papers in
-
- SARS-CoV-2 and COVID-19 Research 10
-
- Bacterial Infections and Vaccines 1
- Journals
- The Lancet (4 papers)Nature Medicine (2 papers)The Lancet Respiratory Medicine (1 paper)Journal of Infection (1 paper)iScience (1 paper)
- Partner nations
- United KingdomUnited StatesUganda
In The Last Decade
Ella Morey
11 papers receiving 7.2k citations
Ella Morey's Hit Papers
Peers
Comparison fields: 5 of 96
- Infectious Diseases 4.7k
- Modeling and Simulation 218
- Health 274
- General Dentistry 5
- Toxicology 40
Countries citing papers authored by Ella Morey
This map shows the geographic impact of Ella Morey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ella Morey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ella Morey more than expected).
Fields of papers citing papers by Ella Morey
This network shows the impact of papers produced by Ella Morey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ella Morey. The network helps show where Ella Morey may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Hit paper breakdown → | 2020 | 3698 |
| 2 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Hit paper breakdown → | 2020 | 1939 |
| 3 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Hit paper breakdown → | 2021 | 894 |
| 4 | 2020 | 481 | |
| 5 | 2020 | 257 | |
| 6 | 2021 | 186 | |
| 7 | 2022 | 31 | |
| 8 | 2023 | 15 | |
| 9 | 2023 | 11 | |
| 10 | 2022 | 9 | |
| 11 | 2023 | 2 |
About Ella Morey
Ella Morey is a scholar working on Infectious Diseases, Microbiology, Nuclear Energy and Engineering, Waste Management and Disposal and Organic Chemistry, having authored 11 papers that have together received 7.5k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (10 papers) and Bacterial Infections and Vaccines (1 paper). The work is most often cited by research in Infectious Diseases (4.7k citations), Modeling and Simulation (218 citations), Health (274 citations), General Dentistry (5 citations) and Toxicology (40 citations). Ella Morey has collaborated with scholars based in United Kingdom, United States and Uganda. Their work appears in journals such as The Lancet, Nature Medicine, The Lancet Respiratory Medicine, Journal of Infection and iScience.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.